AC Immune (NASDAQ:ACIU – Get Free Report) is scheduled to release its earnings data on Friday, April 26th.
AC Immune (NASDAQ:ACIU – Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $16.71 million during the quarter, compared to analysts’ expectations of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AC Immune Trading Down 0.4 %
ACIU stock opened at $2.37 on Thursday. The company’s 50 day moving average is $3.12 and its two-hundred day moving average is $3.34. AC Immune has a twelve month low of $1.78 and a twelve month high of $5.14. The stock has a market cap of $234.39 million, a P/E ratio of -3.34 and a beta of 1.00.
Analyst Ratings Changes
View Our Latest Analysis on ACIU
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Read More
- Five stocks we like better than AC Immune
- How to Choose Top Rated Stocks
- High-Yield Texas Instruments Could Hit New Highs Soon
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is the NASDAQ Stock Exchange?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.